Perrigo New Product Launches, PPA Replacements Slated For August
This article was originally published in The Tan Sheet
Executive Summary
Perrigo expects to offer famotidine Acid Reducer, a generic version of J&J/Merck's Pepcid AC, no later than June, the private labeler told analysts during a conference call May 1.
You may also be interested in...
PFI ANDA
Pharmaceutical Formulations, Inc.'s ibuprofen/pseudoephedrine hydrochloride tablets (Whitehall-Robins' Advil Cold & Sinus) approved by FDA April 8. ANDA 75-588 marks second private label approval referencing the analgesic. Ranbaxy Pharmaceuticals subsidiary Ohm Labs, which licensed its product to Perrigo, received 180-day, first-to-file exclusivity (1"The Tan Sheet" May 7, 2001, p. 8)...
PFI ANDA
Pharmaceutical Formulations, Inc.'s ibuprofen/pseudoephedrine hydrochloride tablets (Whitehall-Robins' Advil Cold & Sinus) approved by FDA April 8. ANDA 75-588 marks second private label approval referencing the analgesic. Ranbaxy Pharmaceuticals subsidiary Ohm Labs, which licensed its product to Perrigo, received 180-day, first-to-file exclusivity (1"The Tan Sheet" May 7, 2001, p. 8)...
PFI ANDA
Pharmaceutical Formulations, Inc.'s ibuprofen/pseudoephedrine hydrochloride tablets (Whitehall-Robins' Advil Cold & Sinus) approved by FDA April 8. ANDA 75-588 marks second private label approval referencing the analgesic. Ranbaxy Pharmaceuticals subsidiary Ohm Labs, which licensed its product to Perrigo, received 180-day, first-to-file exclusivity (1"The Tan Sheet" May 7, 2001, p. 8)...